In silico evaluation of most used drugs on the treatment of slight and mild covid-19 cases in Brazil
International Journal of Development Research
In silico evaluation of most used drugs on the treatment of slight and mild covid-19 cases in Brazil
Received 19th March, 2021; Received in revised form 20th April, 2021; Accepted 01st May, 2021; Published online 30th June, 2021
Copyright © 2021, Bárbara Etruri Ciocca, André Jardini Munhoz and Rubens Maciel Filho. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nowadays, in silico tests are one of the primary and most studied analyses. These tests generate pharmacokinetic and toxicology results for new or existing drugs. It is possible to predict some results that will help future steps in vitro and in vivo. In Brazil, the use of medications free of charge available at SUS is widely used, and there is a constant search to find medicines that can help in the treatment of slight and mild cases of COVID-19. This study searched for the most used drugs at this disease stage and made an in silico assessment of all parameters. All drugs were investigated in previous literature so that the work sought to find an analysis of individual drugs on their characteristics. It was possible to notice that some drugs generate interaction and interfere with each other’s metabolism. It is important to note that this interference or inhibition of metabolism can cause side effects and even toxic effects in the human body. Thus, a more careful analysis is needed to choose the treatment to be more effective to the patient. In silico results indicate the need to avoid the use of nitazoxanide due to its drug interaction.
